Pfizer Inc. shares declined 2.2% in premarket trade Tuesday after the company reported a first-quarter sales miss. Earnings for the latest quarter rose to $3.56 billion, or 59 cents per share, from $3.12 billion, or 51 cents per share in the year-earlier period. Adjusted earnings-per-share were 77 cents, compared with the FactSet consensus of 74 cents. Revenue rose to $12.91 billion from $12.78 billion, compared with the FactSet consensus of $13.14 billion. The latest results include more biosimilar competition for Enbrel in Europe and poor "customer buying patterns" in the U.S. for Ibrance, Xeljanz and certain other products, Pfizer said. The company also saw a 15% operational decline from its sterile injectable pharmaceuticals portfolio, largely because of continued U.S. product shortages. Pfizer shares have slumped 0.6% over the last three months, compared with a 6.2% drop in the S&P 500 and a 7.7% drop in the Dow Jones Industrial Average